Publications
2011
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy
Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.x
Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort
Kigen, G., Kimaiyo, S., Nyandiko, W., Faragher, B., Sang, E., Jakait, B., . . . Khoo, S. H. (2011). Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. PLOS ONE, 6(2). doi:10.1371/journal.pone.0016800
The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir
Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir. Int J STD AIDS, 22, 11-14.
2008
Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir
Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir. CLINICAL INFECTIOUS DISEASES, 47(9), 1222-1225. doi:10.1086/592304
Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication
Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . Khoo, S. (2008). Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication. Antiviral Therapy, 13(5), 675-685.
2006
An update on therapeutic drug monitoring for antiretroviral drugs.
Back, D., Gibbons, S., & Khoo, S. (2006). An update on therapeutic drug monitoring for antiretroviral drugs.. Therapeutic drug monitoring, 28(3), 468-473. doi:10.1097/01.ftd.0000211825.57984.41
2005
The use of therapeutic drug monitoring in the management of protease inhibitor-related toxicity.
Forsyth, S. F., French, P. D., Macfarlane, E., Gibbons, S. E., & Miller, R. F. (2005). The use of therapeutic drug monitoring in the management of protease inhibitor-related toxicity.. International journal of STD & AIDS, 16(2), 139-141. doi:10.1258/0956462053057602
2004
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen
Isaac, A., Taylor, S., Cane, P., Smit, E., Gihbons, S. E., White, D. J., . . . Back, D. J. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 54(2), 498-502. doi:10.1093/jac/dkh357
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
Winston, A., Pozniak, A., Smith, N., Fletcher, C., Mandalia, S., Parmar, D., . . . Nelson, M. (2004). Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?. AIDS (London, England), 18(3), 572-574. doi:10.1097/00002030-200402200-00029
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen
Isaac, A., Taylor, S., Cane, P., Smit, E., Gibbons, S., White, D. J., . . . Back, D. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother, 54(2), 498-502.
2003
Pharmacokinetic drug interactions with nevirapine.
Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine.. Journal of acquired immune deficiency syndromes (1999), 34 Suppl 1, S8-14. doi:10.1097/00126334-200309011-00003
Pharmacokinetic drug interactions with nevirapine
Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr, 34 Sup, S8-S14. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14562853
2002
Therapeutic drug monitoring.
Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring.. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 1(3), 84-85. doi:10.1177/154510970200100301
Therapeutic drug monitoring
Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring. J Int Assoc Physicians AIDS Care (Chic), 1(3), 84-85.
2001
Therapeutic drug monitoring as a tool in treating HIV infection
Khoo, S. H., Gibbons, S. E., & Back, D. J. (2001). Therapeutic drug monitoring as a tool in treating HIV infection. AIDS, 15, S171-S181. doi:10.1097/00002030-200100005-00021
Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users
Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. CLINICAL INFECTIOUS DISEASES, 33(9), 1595-1597. doi:10.1086/322519
Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir
Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., . . . Pillay, D. (2001). Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 48(3), 351-354. doi:10.1093/jac/48.3.351
The role of therapeutic drug monitoring in treatment of HIV infection
Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 52, 89S-96S. Retrieved from https://www.webofscience.com/
The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz
Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(3), 213-217. doi:10.1046/j.1365-2125.2001.00342.x
Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents
Hoggard, P. G., Lloyd, J., Khoo, S. H., Barry, M. G., Dann, L., Gibbons, S. E., . . . Back, D. J. (2001). Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 45(3), 976-980. doi:10.1128/AAC.35.3.976-980.2001
Therapeutic drug monitoring as a tool in treating HIV infection
Khoo, S. H., Gibbons, S. E., & Back, D. J. (2001). Therapeutic drug monitoring as a tool in treating HIV infection. AIDS, 15 Sup, S171-S181. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11816166
2000
Enoximone pharmacokinetics in infants.
Booker, P. D., Gibbons, S., Stewart, J. I., Selby, A., Wilson-Smith, E., & Pozzi, M. (2000). Enoximone pharmacokinetics in infants.. British journal of anaesthesia, 85(2), 205-210. doi:10.1093/bja/85.2.205
Pharmacokinetics of Zidovudine Phosphorylation in Human Immunodeficiency Virus-Positive Thai Patients and Healthy Volunteers
Wattanagoon, Y., Na Bangchang, K., Hoggard, P. G., Khoo, S. H., Gibbons, S. E., Phiboonbhanakit, D., . . . Back, D. J. (2000). Pharmacokinetics of Zidovudine Phosphorylation in Human Immunodeficiency Virus-Positive Thai Patients and Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 44(7), 1986-1989. doi:10.1128/aac.44.7.1986-1989.2000
Therapeutic Drug Monitoring of Antiretrovirals in Human Immunodeficiency Virus Infection
Back, D. J., Khoo, S. H., Gibbons, S. E., Barry, M. G., & Merry, C. (2000). Therapeutic Drug Monitoring of Antiretrovirals in Human Immunodeficiency Virus Infection. Therapeutic Drug Monitoring, 22(1), 122-126. doi:10.1097/00007691-200002000-00026
Current uses and future hopes for clinical pharmacology in the management of HIV infection.
Back, D., Khoo, S., Maher, B., & Gibbons, S. (2000). Current uses and future hopes for clinical pharmacology in the management of HIV infection.. HIV medicine, 1 Suppl 2, 12-17. doi:10.1046/j.1468-1293.2000.00001.x
1999
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
Barry, M., Mulcahy, F., Merry, C., Gibbons, S., & Back, D. (1999). Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.. Clinical pharmacokinetics, 36(4), 289-304. doi:10.2165/00003088-199936040-00004
1997
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
Merry, C., Barry, M. G., Mulcahy, F., Ryan, M., Heavey, J., Tjia, J. F., . . . Back, D. J. (1997). Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS, 11(4), F29-F33. doi:10.1097/00002030-199704000-00001
Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.
Merry, C., Mulcahy, F., Barry, M., Gibbons, S., & Back, D. (1997). Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.. AIDS (London, England), 11(2), 268-269.
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Barry, M., Gibbons, S., Back, D., & Mulcahy, F. (1997). Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.. Clinical pharmacokinetics, 32(3), 194-209. doi:10.2165/00003088-199732030-00003
1996
Improved tolerability of ritonavir derived from pharmacokinetic principles.
Merry, C., Barry, M., Gibbons, S., Mulcahy, F., & Back, D. (1996). Improved tolerability of ritonavir derived from pharmacokinetic principles.. British journal of clinical pharmacology, 42(6), 787. doi:10.1046/j.1365-2125.1996.d01-3339.x
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites
Barry, M. G., Khoo, S. H., Veal, G. J., Hoggard, P. G., Gibbons, S. E., Wilkins, E. G. L., . . . Back, D. J. (1996). The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS, 10(12), 1361-1367. doi:10.1097/00002030-199610000-00008
1995
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
Gibb, D., Barry, M., Ormesher, S., Nokes, L., Seefried, M., Giaquinto, C., & Back, D. (1995). Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.. British journal of clinical pharmacology, 39(5), 527-530. doi:10.1111/j.1365-2125.1995.tb04490.x
1994
'Didanosine - a clinical and biochemical investigation'
Gibbons, S. E. (1994). 'Didanosine - a clinical and biochemical investigation'. (Master's Thesis, The University of Liverpool).
PHARMACOKINETICS OF ZIDOVUDINE AND DIDEOXYINOSINE ALONE AND IN COMBINATION IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME
BARRY, M., HOWE, J. L., ORMESHER, S., BACK, D. J., BRECKENRIDGE, A. M., BERGIN, C., . . . NYE, F. (1994). PHARMACOKINETICS OF ZIDOVUDINE AND DIDEOXYINOSINE ALONE AND IN COMBINATION IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 37(5), 421-426. doi:10.1111/j.1365-2125.1994.tb05708.x
1993
METABOLISM OF DIDANOSINE (DDI) BY ERYTHROCYTES - PHARMACOKINETIC IMPLICATIONS
BARRY, M., BACK, D., ORMESHER, S., BEECHING, N., & NYE, F. (1993). METABOLISM OF DIDANOSINE (DDI) BY ERYTHROCYTES - PHARMACOKINETIC IMPLICATIONS. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 36(1), 87-88. doi:10.1111/j.1365-2125.1993.tb05899.x
1992
METABOLISM OF 2',3'-DIDEOXYINOSINE (DDI) IN HUMAN BLOOD
BACK, D. J., ORMESHER, S., TJIA, J. F., & MACLEOD, R. (1992). METABOLISM OF 2',3'-DIDEOXYINOSINE (DDI) IN HUMAN BLOOD. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 33(3), 319-322. doi:10.1111/j.1365-2125.1992.tb04043.x
Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.
Kuhnz, W., al-Yacoub, G., Power, J., Ormesher, S. E., Back, D. J., & Jütting, G. (1992). Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.. Arzneimittel-Forschung, 42(9), 1142-1146.